175696-50-1

Basic information

• Product Name: N-tert-Butyloxycarbonyl-D-ribo-phytosphingosine
• Synonyms: N-tert-Butyloxycarbonyl-D-ribo-phytosphingosine
• CAS NO: 175696-50-1
• Molecular Formula: C₂₃H₄₇NO₅
• Molecular Weight: 417.62298
• Product Categories: Amines, Chiral Reagents, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 175696-50-1.mol
• Article Data: 33

Chemical Properties

• Appearance: /
• Storage Temp.: Refrigerator
• Solubility: Dichloromethane
• CAS DataBase Reference: N-tert-Butyloxycarbonyl-D-ribo-phytosphingosine(CAS DataBase Reference)
• NIST Chemistry Reference: N-tert-Butyloxycarbonyl-D-ribo-phytosphingosine(175696-50-1)
• EPA Substance Registry System: N-tert-Butyloxycarbonyl-D-ribo-phytosphingosine(175696-50-1)

Safety Data

• Hazardous Substances Data: 175696-50-1(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Uses

Protected D-ribo-Phytosphingosine (P398990). A natural compound with antifungal activity.

Upstream product

• 554-62-1 D-ribo-phytosphingosine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 3144-09-0 methanesulfonamide 
• 214556-61-3 (2R,3Z)-2-(tert-butoxycarbonyl)amino-3-octadecen-1-ol 
• 122709-20-0 N-(tert-butoxycarbonyl)-L-serine N'-methoxy-N'-methylamide 
• 122709-21-1 (4S)-2,2-Dimethyl-4-(N-methoxy-N-methylcarbamoyl)oxazolidin-3-carbonsaeure-(tert-butyl)ester 
• 3262-72-4 (S)-N-(tert-butoxycarbonyl)serine 
• 629-72-1 pentadecyl bromide 
• 1429195-22-1 C₂₇H₅₁NO₇ 
• 1332640-34-2 (R)-1-{(4R,5S)-5-[(S)-1-(benzylamino)allyl]-2,2-dimethyl-1,3-dioxolan-4-yl}-2-(tert-butyldimethylsilyloxy)ethanol 
• 1332640-41-1 (2S,3S,4r,Z)-2-(benzylamino)octadec-5-ene-1,3,4-triol 
• 1332640-40-0 (S)-3-benzyl-4-((4S,5R)-2,2-dimethyl-5-((Z)-tetradec-1-enyl)-1,3-dioxolan-4-yl)oxa-zolidin-2-one 
• 1332640-38-6 (S)-3-benzyl-4-((4S,5R)-5-((R)-1,2-dihydroxyethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)-oxazolidin-2-one 
• 1332640-37-5 3-benzyl-4-((4S,5R)-5-((R)-2-(tert-butyldimethylsilyloxy)-1-hydroxyethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)oxazolidin-2-one 

Downstream Products

• 1340475-40-2 (4S,5S)-5-((R)-1-hydroxypentadecyl)-4-(trityloxymethyl)oxazolidin-2-one 
• 1340475-39-9 tert-butyl ((2S,3S,4R)-3,4-dihydroxy-1-(trityloxy)octadecan-2-yl)carbamate 
• 1262283-63-5 (4S,5S,6S)-4-((tert-butyldiphenylsilyloxy)methyl)-2-oxo-6-tetradecyl-1,3-oxazinan-5-yl trifluoromethanesulfonate 
• 1262283-61-3 (R)-1-((4S,5R)-4-((tert-butyldiphenylsilyloxy)methyl)-2-oxooxazolidin-5-yl)pentadecyl methanesulfonate 
• 1262283-60-2 (4S,5S,6S)-4-((tert-butyldiphenylsilyloxy)methyl)-2-oxo-6-tetradecyl-1,3-oxazinan-5-yl methanesulfonate 
• 1262283-59-9 (2S,3S,4R)-1-(tert-butyldiphenylsilyloxy)-2-[N-(tert-butyloxycarbonyl)amino]octadecan-3,4-diol dimethanesulfonate 
• 1262283-55-5 (4S,5S,6S)-4-((tert-butyldiphenylsilyloxy)methyl)-5-hydroxy-6-tetradecyl-1,3-oxazinan-2-one 
• 1262283-54-4 (4S,5R)-4-((tert-butyldiphenylsilyloxy)methyl)-5-((R)-1-hydroxypentadecyl)oxazolidin-2-one 
• 1262283-52-2 (2S,3S,4R)-1-(tert-butyldiphenylsilyloxy)-2-[N-(tert-butyloxycarbonyl)amino]octadecan-3,4-cyclic sulfate 
• 1262283-53-3 C₃₉H₆₃NO₆SSi 
• 1224436-76-3 (2S,3S,4R)-1-(tert-butyldiphenylsilyloxy)-2-[N-(tert-butyloxycarbonyl)amino]octadecan-3,4-diol 
• 898531-99-2 (2S,3S,4R)-1-O-(6-deoxy-6-acetamido-α-D-galactopyranosyl)-2-(N-nervonoylamino)-1,3,4-octadecanetriol 
• 1089188-04-4 (2S,3S,4R)-1-O-(6-deoxy-6-phenylaminocarbonylamino-α-D-galactopyranosyl)-2-[(N-hexacosanoyl)amino]octadecane-3,4-diol 
• 116467-63-1 N-tert-butyloxycarbonylsphingosine 

Relevant articles and documents

A practical and scalable synthesis of KRN7000 using glycosyl iodide as the glycosyl donor

KRN7000 is particularly useful because it is a powerful and specific CD1d agonist and has prompted intense interest in the context of immunology in the past 25 years. Its limited commercial availability and high price has led to the publication of many different syntheses. However, almost all of them focused on the methodology development rather than a scalable synthesis. Herein, we have described a practical and scalable procedure for the synthesis of KRN7000 basing on the glycosyl iodide method. This procedure involves total of eight steps to obtain the highly pure product KNR7000 on gram scale from the commercially available starting materials (d-galactose and the phytosphingosine) with only three column chromatographic purifications.

4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO

Disclosed are halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections. Such viral infections can include tongaviridae, bunyaviridae, arenaviridae, coronaviridae, flaviviridae, picornaviridae, Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infections.

NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO

This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.